Reasons for stopping drugs are monitored in New Zealand
BMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7059.756 (Published 21 September 1996) Cite this as: BMJ 1996;313:756- David M Coulter, Director, intensive medicines monitoring programme
- National Toxicology Group, Dunedin School of Medicine, PO Box 913, Dunedin, New Zealand
EDITOR,—The New Zealand intensive medicines monitoring programme is a system for monitoring adverse events in the early postmarketing period of selected new drugs. Each drug is monitored for four to five years usually, and cohorts of identifiable patients are established from prescription information sent in from virtually all pharmacies throughout the country, with a population base of 3.6 million. The average size of each cohort is 10 228. Each dispensing episode is recorded throughout the monitoring period; the data include date, daily …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.